The Pharma Data

MARCH 7, 2022

Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. The IGA results in the equivalent genotype (genetic make-up) and short-hair coat trait seen in some conventionally bred cattle, known as a “slick” coat. Today, the U.S.

Genome 52

Genome Genomics Production Marketing 52

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. At present, most antibody tests on the market require samples to be sent to a lab for analysis.

DNA 52

DNA Antibody Research Genome 52

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. NGS Library Preparation Kits Market. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries.

Genetics 52

Genetics DNA RNA Reagent 52

Pharmaceutical Technology

MARCH 28, 2023

The gene-editing technology allows for precise, directed changes to genomic DNA. It edits genes by precisely cutting DNA, then allowing natural DNA repair processes to take over. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Drug Discovery World

SEPTEMBER 7, 2022

NICE has judged olaparib too expensive partly because of the cost of genetic testing to tailor the drug for patients. Olaparib, which was initially developed to treat women with ovarian and breast cancer, is part of a family of drugs called PARP inhibitors that target and kill cancer cells with faulty DNA repair machinery.

Genetics 52

Genetics Drugs DNA Gene 52

XTalks

JUNE 16, 2023

XTALKS WEBINAR: Point-of-Care Diagnostics: Best Practices for Bringing Novel Solutions to Market Live and On-Demand: Thursday, July 13, 2023, at 1pm EDT (10am PDT) Register for this free webinar to gain insights from industry leaders on best practices for commercializing point-of-care diagnostic innovations. . billion in 2022 to $15.91

FDA Approval 97

FDA Approval Genome Genomics DNA 97

Pharmaceutical Technology

FEBRUARY 23, 2023

The collaboration will combine the mRNA platform of Moderna with the gene editing technologies suite, including the base editing capabilities of Life Edit for the development of curative therapies to treat challenging genetic diseases. Life Edit will get an upfront payment and is eligible for potential milestone payments.

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Drug Discovery World

FEBRUARY 6, 2024

Verge Genomics’ potential amyotrophic lateral sclerosis (ALS) treatment VRG50635 is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform 6. Automation is also being applied to genomics sample preparation, an area that requires particular robustness and scalability.

Marketing 69

Marketing Medicine Genome Genomics 69

pharmaphorum

OCTOBER 12, 2022

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data generated from “omics” studies.

Genome 64

Genome Genomics DNA Drugs 64

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Regeneron Pharmaceuticals is the leading patent filer in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, which are proteins that can be used to edit genomes by knocking select genes in or out to specifically modify DNA sequences.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Drug Discovery World

JUNE 5, 2023

The panel was moderated by Alexander Nuyken, Head Life Sciences Markets Europe, Middle East & Africa, JLL. I consider one of my responsibilities to advocate the advent of a new era for 3D genomics. Our final goal is to pioneer the 3D genomic field and demonstrate the impact on precision medicine.

Genome 52

Genome Genomics Life Science Genetics 52

The Pharma Data

JANUARY 31, 2021

Illumina , the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a life sciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

Life Science 52

Life Science Genome Genomics Reagent 52

The Pharma Data

DECEMBER 22, 2020

This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. “We are truly excited and humbled to bring the power of diagnostic microarray testing to the Japanese market. About Agilent Technologies.

Genome 40

Genome Genomics Genetics In-Vitro 40

Drug Discovery World

APRIL 17, 2024

JMB: There’s no doubt that it’s been a tough environment to raise funds, and the market has only worsened in 2023. JMB: Hundreds of genetic diseases involve a missing or deficient protein and/or enzyme. Our approach is aimed at genetic diseases where amplifying healthy protein can offer therapeutic benefits.

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Cloudbyz

MARCH 6, 2024

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 75

Gene Immune Response Manufacturing Gene Therapy 75

Delveinsight

JANUARY 14, 2021

The multi-arm trial will gauge various combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. Verve Therapeutics unveils its lead program for treating genetically high cholesterol.

Gene Editing 40

Gene Editing Gene Genetics DNA 40

Drug Discovery World

OCTOBER 16, 2023

From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). Emerging UK biotech firms like Mosaic Therapeutics, Enhanc3D Genomics, and Nucleome Therapeutics are using these genomic insights to innovate.”

Drugs 76

Drugs Life Science Gene Therapy Genome 76

XTalks

DECEMBER 4, 2023

In a statement outlining its investigation, the FDA said it received reports of the T-cell malignancies from clinical trials and post-marketing safety monitoring. The vectors can potentially cause cancer by inserting genetic material into a patient’s genome, particularly near cancer-related DNA sequences or suppressors​​​​.

Gene Therapy 69

Gene Therapy Gene Clinical Trials Clinical Trials 69

The Pharma Data

OCTOBER 19, 2020

By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, physicians from Winship will be able to further prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. Europe , Asia and other international markets.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

Drug Discovery World

MARCH 27, 2023

Genomics is driving a revolution in drug development and, in the long run, the state of public healthcare. The first draft human genome took a decade to create, and 13 years to complete. Advances in sequencing are leading to scientific breakthroughs in preventative care, faster diagnoses, and proactive medical interventions.

Genome 52

Genome Genomics Research Scientist 52

XTalks

DECEMBER 13, 2023

Moreover, it has submitted global marketing authorization applications for mRNA-1345, a vaccine designed to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD), supported by favorable data from a predefined interim analysis. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA).

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Roots Analysis

FEBRUARY 15, 2022

Gene engineering based on recombination was pioneered in the mid-1990s; Currently, development of gene editing technologies has opened up the possibility of modifying genomic sequences in both eukaryotic and prokaryotic organisms. Genome Editing is a way of making changes in the DNA. Type of Genome Editing: Zinc-Finger Nuclease.

Genome 52

Genome Genomics Gene Editing DNA 52

Roots Analysis

AUGUST 31, 2023

Recent advances in DNA sequencing technologies have led to significant developments in healthcare-focused research on precision medicine and diagnostics. Nutrigenomics is the science studying the relationship between human genome, nutrition and health.

Genome 40

Genome Genomics Genetics Gene 40

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.

Vaccination 52

Vaccination Vaccine DNA Protein 52

XTalks

DECEMBER 20, 2023

Given its ability to precisely edit genes, there is tremendous promise for the revolutionary technology to offer cures for genetic disorders and to treat various diseases. The global wearable medical devices market size was valued at $73.77 This year, the very first CRISPR-based therapy received FDA approval for sickle cell disease.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. Biomarker discovery is becoming a vibrant area for exploiting the power of AI and ML.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

MARCH 6, 2024

The development of effective new disease-modifying treatments in neurodegenerative and neuropsychiatric disorders has been hindered by their inherent genetic complexity, environmental influences, and clinical variability. This is comparatively easier to accomplish in these diseases because they are relatively monogenic.

Genome 65

Genome Genomics Clinical Trials Clinical Trials 65

Roots Analysis

AUGUST 17, 2023

Genome sequencing has historically been classified into DNA sequencing and RNA sequencing. DNA sequencing generates data that is very robust, reproducible, insightful, and can be applied to genes having different expression level by selecting genomic region. between 2022 and 2035.

RNA 52

RNA DNA Genome Genomics 52

Drug Discovery World

NOVEMBER 15, 2022

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 98

DNA Drugs Antibody Engineer 98

The Pharma Data

NOVEMBER 24, 2020

Lynparza exploits tumour DNA damage response (DDR) in cells/tumours harbouring a deficiency in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2 , to selectively kill cancer cells. Germline genetic testing in prostate cancer – further enrichment in variant histologies? Prostate cancer statistics.

Gene 52

Gene Hormones DNA Medicine 52

Drug Discovery World

JULY 26, 2023

With 100-fold the number of genes in the human genome 1 , this microbial collection is a rich genetic signature of clinical significance that we have only recently gained the tools to explore. Genome editing tools such as CRISPR may be employed to create “live biotherapeutics” (drugs composed of living bacteria).

Medicine 52

Medicine Genome Genomics Bioinformatics 52

pharmaphorum

SEPTEMBER 13, 2022

Thanks to the dedicated efforts of doctors, patients, carers, and healthcare professionals, people diagnosed with blood cancer are now living longer, with a steady stream of more effective treatments entering the market each year. 2012 – The 100,000 Genomics Project begins. This was an entirely new approach to DNA research.

Genome Project 98

Genome Project Genome Genomics DNA 98